Riskpilot← Back to searchSign inGet full accessMEDI ENGROS AS
ASActiveOrg 919417382Grimerudvegen 19A, 2312 OttestadWholesale of pharmaceutical and medical goods · NACE 4646Est. 20170 employees
Revenue 2022
NOK 0
EBITDA margin
—
+48% vs 2021
Equity ratio
-734.4%
Financial strength
Net profit 2022
NOK -5K
+66% vs 2021
| Revenue | NOK 0 | — |
| EBITDA | NOK -5K | +48% |
| Net profit | NOK -5K | +66% |
| Total assets | NOK 6K | -47% |
| Equity | NOK -44K | -14% |
| Employees | 0 | — |
Legal name
MEDI ENGROS AS
Org number
919417382
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. august 2017
Share capital
NOK 3 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Company purpose
Import og salg av medisinsk utstyr, samt utleie av utstyr, og andre produkter/tjenester som naturlig hører sammen med dette, herunder å delta i andre selskap med lignende virksomhet, og kjøp og salg av aksjer eller på annen måte gjøre seg interessert i andre foretak.
Address
Grimerudvegen 19A, 2312 Ottestad
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 111 | 0 | 41 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 17 | −9 | 3 | −11 | −5 |
| Depreciation & amort. | −16 | −22 | −22 | −6 | −0 |
| EBIT | 1 | −30 | −18 | −16 | −5 |
| Net financials | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | −30 | −18 | −16 | −5 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 1 | −30 | −18 | −16 | −5 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 76 | 46 | 28 | 11 | 6 |
| Equity | 25 | −5 | −23 | −39 | −44 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 50 | 50 | 50 | 50 | 50 |
| Total debt | 50 | 50 | 50 | 50 | 50 |
EBITDA margin
-543900.0%
This company
15.8%
Market median
-3442505% vs market
20182022
Equity ratio
-734.4%
This company
38.2%
Market median
-2023% vs market
20182022
Return on equity
-543900.0%
This company
18.4%
Market median
-2956078% vs market
20182022
Net profit margin
-543900.0%
This company
8.1%
Market median
-6714915% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
1.14×
This company
0.62×
Market median
-84% vs market
20182022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2017 | |
| Chairman | 2017 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MEDI ENGROS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gabriella Valeria Hütter | Board of Directors | 0 companies |
| Endre Balazs | Chairman | 0 companies |